Samsara Biocapital, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Samsara Biocapital, LLC reported 35 stock positions worth $560.8 million. Its top holding was Scholar Rock (SRRK) at 32.2% of the portfolio, followed by Kalaris Therapeutics (KLRS, 16.4%) and Mineralys Therapeutics (MLYS, 16.1%). Compared with Q4 2024, it opened 2 new positions, sold out of 8, added to 2 and reduced 8. The biggest buy was a new position in Kalaris Therapeutics (KLRS) and the biggest sale Upstream Bio (UPB, shares −7%).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001744967
- Portfolio Value
- $560.8M (Q1 2025)
- SEC Filing
- 0001415889-25-013106 ↗ filed May 15, 2025
Holdings Value
Holdings 35 stocks · $560.8M
| SRRK Scholar Rock Holding Corp. | 32.18% | 5,612,896 | $180.5M | No change |
| KLRS Kalaris Therapeutics Inc. | 16.39% | 11,448,081 | $91.9M | New |
| MLYS Mineralys Therapeutics Inc. | 16.07% | 5,674,916 | $90.1M | Add +11.8% |
| NGNE Neurogene Inc. | 3.59% | 1,717,127 | $20.1M | No change |
| ALMS Alumis Inc. | 3.58% | 3,266,498 | $20.1M | No change |
| PVLA Palvella Therapeutics Inc. | 3.39% | 679,486 | $19.0M | No change |
| SEPN Septerna Inc. | 3.25% | 3,149,128 | $18.2M | Add +13.8% |
| CRGX Cargo Therapeutics Inc. | 3.20% | 4,415,689 | $18.0M | No change |
| LENZ Lenz Therapeutics Inc. | 2.41% | 526,390 | $13.5M | Reduce -46.7% |
| UPB Upstream Bio Inc. | 2.26% | 2,067,146 | $12.7M | Reduce -6.8% |
| ACLX Arcellx Inc. | 1.58% | 135,276 | $8.9M | Reduce -46.7% |
| ZYME Zymeworks Inc. | 1.42% | 666,667 | $7.9M | Reduce -33.3% |
| AVDL Avadel Pharmaceuticals Ltd. | 1.35% | 967,527 | $7.6M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 1.30% | 138,118 | $7.3M | Reduce -20.0% |
| NKTX Nkarta Inc. | 1.24% | 3,768,035 | $6.9M | No change |
| GOSS Gossamer Bio Inc. | 1.20% | 6,130,268 | $6.7M | No change |
| SLRN Acelyrin Inc. | 1.11% | 2,523,022 | $6.2M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 0.73% | 588,816 | $4.1M | No change |
| VTVT VTV Therapeutics Inc. Class A | 0.64% | 206,784 | $3.6M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.63% | 824,155 | $3.5M | No change |
| SRZN Surrozen Inc. | 0.50% | 241,400 | $2.8M | New |
| ABVX Abivax SA-ADR | 0.47% | 425,000 | $2.7M | Reduce -50.0% |
| STRO Sutro Biopharma Inc. Com SHS | 0.25% | 2,196,814 | $1.4M | No change |
| INZY Inozyme Pharma Inc. | 0.25% | 1,562,500 | $1.4M | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.16% | 291,666 | $875K | No change |
| TNGX Tango Therapeutics Inc. | 0.15% | 630,000 | $863K | No change |
| PRME Prime Medicine Inc. | 0.14% | 405,228 | $806K | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.13% | 2,442,352 | $745K | No change |
| HLVX Hillevax Inc. | 0.10% | 399,637 | $579K | No change |
| TERN Terns Pharmaceuticals Inc. | 0.10% | 202,348 | $558K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.07% | 1,049,153 | $420K | No change |
| CRIS Curis Inc. | 0.07% | 185,943 | $390K | Reduce -6.2% |
| LYRA Lyra Therapeutics Inc. | 0.03% | 1,390,130 | $176K | Reduce -29.3% |
| KRON Kronos Bio Inc. | 0.01% | 78,131 | $64K | No change |
| ALLK Allakos LLC | 0.01% | 172,089 | $39K | No change |
Other holdings (2): bonds, preferreds, convertibles and warrants · $46K (not counted above)
Total filed on the 13F, all lines: $560.8M.
Portfolio Sells Q4 2024 → Q1 2025
| UPB Upstream Bio Inc. | Reduce -6.8% | 2.26% | −2.75 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −1.72 |
| LENZ Lenz Therapeutics Inc. | Reduce -46.7% | 2.41% | −1.50 |
| ACLX Arcellx Inc. | Reduce -46.7% | 1.58% | −1.09 |
| ACRS Aclaris Therapeutics Inc. | Sold out | 0.00% | −0.81 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.64 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.62 |
| ZYME Zymeworks Inc. | Reduce -33.3% | 1.42% | −0.59 |
| ABVX Abivax SA-ADR | Reduce -50.0% | 0.47% | −0.38 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −0.26 |
| IMTX Immatics NV | Sold out | 0.00% | −0.19 |
| JANX Janux Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| LYRA Lyra Therapeutics Inc. | Reduce -29.3% | 0.03% | −0.02 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -20.0% | 1.30% | −0.02 |
| CRIS Curis Inc. | Reduce -6.2% | 0.07% | −0.01 |
| ALLOVIR INC | Sold out | 0.00% | −0.00 |
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 24 | $1.2B | SRRK, ALMS, MLYS, SEPN, ALMR |
| Q1 2026 | 22 | $1.0B | SRRK, MLYS, ALMS, SEPN, KLRS |
| Q4 2025 | 20 | $969.2M | SRRK, MLYS, KLRS, SEPN, ALMS |
| Q3 2025 | 25 | $765.9M | MLYS, SRRK, KLRS, SEPN, NGNE |
| Q2 2025 | 27 | $488.9M | SRRK, MLYS, SEPN, KLRS, NGNE |
| Q1 2025 | 35 | $560.8M | SRRK, KLRS, MLYS, NGNE, ALMS |
| Q4 2024 | 41 | $728.6M | SRRK, CRGX, SEPN, MLYS, NGNE |
| Q3 2024 | 40 | $520.3M | CRGX, MLYS, SRRK, NGNE, ALMS |
| Q2 2024 | 38 | $477.8M | CRGX, MLYS, SRRK, NGNE, ACLX |
| Q1 2024 | 37 | $646.3M | SRRK, CRGX, MLYS, NGNE, NKTX |